(Q38094875)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23545492%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

title

Genomic aspects of NAFLD pathogenesis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23545492%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

0 references

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23545492%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Damjana Rozman

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23545492%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

author name string

Adviti Naik

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23545492%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

publication date

29 March 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23545492%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23545492%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

volume

102

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23545492%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23545492%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

page(s)

84-95

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23545492%20AND%20SRC:MED&resulttype=core&format=json

Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus

27 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Hepatic histology in obese patients undergoing bariatric surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

7 January 2021

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

7 January 2021

Hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Non-viral causes of hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Hepatocellular carcinoma occurring in nonfibrotic liver: Epidemiologic and histopathologic analysis of 80 French cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Nonalcoholic Fatty liver disease: focus on lipoprotein and lipid deregulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Histopathology of nonalcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Nonalcoholic steatohepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Effects of nuclear receptor FXR on the regulation of liver lipid metabolism in patients with non-alcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob/ob mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Molecular Interactions between NAFLD and Xenobiotic Metabolism.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Steatohepatitis: a tale of two "hits"?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

7 January 2021

From fat to inflammation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Hepatic free cholesterol accumulates in obese, diabetic mice and causes nonalcoholic steatohepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Disruption of endoplasmic reticulum structure and integrity in lipotoxic cell death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Beyond insulin resistance in NASH: TNF-alpha or adiponectin?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Liver adenosine monophosphate-activated kinase-alpha2 catalytic subunit is a key target for the control of hepatic glucose production by adiponectin and leptin but not insulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Increased soluble leptin receptor levels in morbidly obese patients with insulin resistance and nonalcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Loss of resistin ameliorates hyperlipidemia and hepatic steatosis in leptin-deficient mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Increased serum resistin in nonalcoholic fatty liver disease is related to liver disease severity and not to insulin resistance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Insulin resistance and whole body energy homeostasis in obese adolescents with fatty liver disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Adipokines in liver diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Nonalcoholic fatty liver disease: Cytokine-adipokine interplay and regulation of insulin resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Obesity affects the liver - the link between adipocytes and hepatocytes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Mechanisms of disease progression in nonalcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Non-alcoholic fatty liver disease as a risk factor for hepatocellular carcinoma: mechanisms and implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Unsaturated fatty acids promote hepatoma proliferation and progression through downregulation of the tumor suppressor PTEN.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Saturated fatty acids induce endoplasmic reticulum stress and apoptosis independently of ceramide in liver cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Integrated hepatic transcriptome and proteome analysis of mice with high-fat diet-induced nonalcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Functional proteomic analysis of nonalcoholic fatty liver disease in rat models: enoyl-coenzyme a hydratase down-regulation exacerbates hepatic steatosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

A systems biology approach to the pathogenesis of obesity-related nonalcoholic fatty liver disease using reverse phase protein microarrays for multiplexed cell signaling analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Plasma metabolomic profile in nonalcoholic fatty liver disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

An integrated reverse functional genomic and metabolic approach to understanding orotic acid-induced fatty liver

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Gene expression patterns in hepatic tissue and visceral adipose tissue of patients with non-alcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Hepatic gene expression of Caucasian and African-American patients with obesity-related non-alcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Genetic and epigenetic variants influencing the development of nonalcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Single nucleotide polymorphisms and risk of hepatocellular carcinoma in cirrhosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Nonalcoholic steatohepatitis and noncirrhotic hepatocellular carcinoma: fertile soil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Distinct regulation of adiponutrin/PNPLA3 gene expression by the transcription factors ChREBP and SREBP1c in mouse and human hepatocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Pnpla3/Adiponutrin deficiency in mice does not contribute to fatty liver disease or metabolic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

A multi-ethnic study of a PNPLA3 gene variant and its association with disease severity in non-alcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

The impact of patatin-like phospholipase domain-containing protein 3 polymorphism on hepatocellular carcinoma prognosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

PNPLA3 rs738409C/G polymorphism in cirrhosis: relationship with the aetiology of liver disease and hepatocellular carcinoma occurrence.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in non-alcoholic steatohepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

The SOD2 C47T polymorphism influences NAFLD fibrosis severity: Evidence from case-control and intra-familial allele association studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Myeloperoxidase and superoxide dismutase 2 polymorphisms comodulate the risk of hepatocellular carcinoma and death in alcoholic cirrhosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Biological functions of tumor necrosis factor cytokines and their receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Adipokines: the missing link between insulin resistance and obesity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Tumour necrosis factor gene polymorphism and disease prevalence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Influence of polygenetic polymorphisms on the susceptibility to non-alcoholic fatty liver disease of Chinese people.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Influence of TNF gene polymorphisms in Japanese patients with NASH and simple steatosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Genetic polymorphisms of adiponectin and tumor necrosis factor-alpha and nonalcoholic fatty liver disease in Chinese people

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Association of tumor necrosis factor-α gene promoter polymorphism at sites -308 and -238 with non-alcoholic fatty liver disease: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Polymorphisms of tumor necrosis factor-alpha and hepatocellular carcinoma risk: a HuGE systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Tumor necrosis factor-alpha in the pathogenesis and treatment of cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Association between combinations of glutathione-S-transferase M1, T1 and P1 genotypes and non-alcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Null genotypes of GSTM1 and GSTT1 contribute to hepatocellular carcinoma risk: evidence from an updated meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Null genotypes of GSTM1 and GSTT1 contribute to increased risk of diabetes mellitus: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Null genotypes of GSTM1 and GSTT1 contribute to male factor infertility risk: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Peroxisome proliferator-activated receptor alpha target genes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Cloning of adiponectin receptors that mediate antidiabetic metabolic effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Effects of fibrates on serum lipids and atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

A Val227Ala polymorphism in the peroxisome proliferator activated receptor alpha (PPARalpha) gene is associated with variations in serum lipid levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Association of V227A PPARalpha polymorphism with altered serum biochemistry and alcohol drinking in Japanese men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

A Val227Ala substitution in the peroxisome proliferator activated receptor alpha (PPAR alpha) gene associated with non-alcoholic fatty liver disease and decreased waist circumference and waist-to-hip ratio

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

PGC-1alpha deficiency causes multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic steatosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Epigenetic regulation of insulin resistance in nonalcoholic fatty liver disease: impact of liver methylation of the peroxisome proliferator-activated receptor γ coactivator 1α promoter.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Association between PPARGC1A polymorphisms and the occurrence of nonalcoholic fatty liver disease (NAFLD).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Berberine reduces methylation of the MTTP promoter and alleviates fatty liver induced by a high-fat diet in rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Polymorphism in microsomal triglyceride transfer protein: a link between liver disease and atherogenic postprandial lipid profile in NASH?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

An unexpected requirement for phosphatidylethanolamine N-methyltransferase in the secretion of very low density lipoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Polymorphism of the PEMT gene and susceptibility to nonalcoholic fatty liver disease (NAFLD)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

The phosphatidylethanolamine N-methyltransferase gene V175M single nucleotide polymorphism confers the susceptibility to NASH in Japanese population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Foxo1 mediates insulin action on apoC-III and triglyceride metabolism.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Dissociation between APOC3 variants, hepatic triglyceride content and insulin resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Lack of effect of apolipoprotein C3 polymorphisms on indices of liver steatosis, lipid profile and insulin resistance in obese Southern Europeans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Genetic variation in PNPLA3 but not APOC3 influences liver fat in non-alcoholic fatty liver disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Deficiency in apolipoprotein E has a protective effect on diet-induced nonalcoholic fatty liver disease in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Involvement of apolipoprotein E in excess fat accumulation and insulin resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Association of apolipoprotein E polymorphisms in patients with non-alcoholic steatohepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Apolipoprotein E gene polymorphism in nonalcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Adiponectin gene polymorphisms modulate acute adiponectin response to dietary fat: Possible pathogenetic role in NASH.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Genetic determinants of hepatic steatosis in man.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Adiponectin and adiponectin receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Genetic variation in the ADIPOR2 gene is associated with liver fat content and its surrogate markers in three independent cohorts.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

From the metabolic syndrome to NAFLD or vice versa?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Essential roles of growth hormone (GH) and insulin-like growth factor-I (IGF-I) in the liver

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Insulin-like growth factor 1 (IGF-1): a growth hormone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

GH-independent IGF-I action is essential to prevent the development of nonalcoholic steatohepatitis in a GH-deficient rat model.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Nonalcoholic fatty liver disease is associated with increased GHBP and reduced GH/IGF-I levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Role of growth hormone, insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 in development of non-alcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Metabolic parameters and nonalcoholic fatty liver disease in hypopituitary men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Growth Hormone Reverses Nonalcoholic Steatohepatitis in a Patient With Adult Growth Hormone Deficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Genotypes associated with lipid metabolism contribute to differences in serum lipid profile of GH-deficient adults before and after GH replacement therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

IGF-1, IGFBP-1, and IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: findings from the Breast and Prostate Cancer Cohort Consortium (BPC3).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Plasma interleukin-6, tumour necrosis factor alpha and blood cytokine production in type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Genetic polymorphisms in non-alcoholic fatty liver disease: interleukin-6-174G/C polymorphism is associated with non-alcoholic steatohepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

A novel pregnane X receptor-mediated and sterol regulatory element-binding protein-independent lipogenic pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

The nuclear receptor PXR gene variants are associated with liver injury in nonalcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Variants in the UGT1A1 Gene and the Risk of Pediatric Nonalcoholic Fatty Liver Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Polymorphisms of MRP2 (ABCC2) are associated with susceptibility to nonalcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Association between liver-specific gene polymorphisms and their expression levels with nonalcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

The interplay of cis-regulatory elements rules circadian rhythms in mouse liver

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Histone methyltransferase MLL3 contributes to genome-scale circadian transcription

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Circadian regulation of the hepatic endobiotic and xenobitoic detoxification pathways: the time matters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

7 January 2021

The meter of metabolism

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Circadian rhythm of cholesterol synthesis in mouse liver: a statistical analysis of the post-squalene metabolites in wild-type and Crem-knock-out mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Circadian expression of steroidogenic cytochromes P450 in the mouse adrenal gland--involvement of cAMP-responsive element modulator in epigenetic regulation of Cyp17a1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Metabolism and cancer: the circadian clock connection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Identification of small molecule activators of cryptochrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Circadian desynchrony promotes metabolic disruption in a mouse model of shiftwork

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Circadian clock genes Per1 and Per2 regulate the response of metabolism-associated transcripts to sleep disruption

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Cytochrome P450s in the synthesis of cholesterol and bile acids--from mouse models to human diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Defects in cholesterol synthesis genes in mouse and in humans: lessons for drug development and safer treatments.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Diurnal variation in vascular and metabolic function in diet-induced obesity: divergence of insulin resistance and loss of clock rhythm

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Chronic mild stress alters circadian expressions of molecular clock genes in the liver

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Diurnal variation of hepatic antioxidant gene expression in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

The circadian clock and metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Shift work is a risk factor for increased total cholesterol level: a 14-year prospective cohort study in 6886 male workers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Altered circadian rhythm of the clock genes in fibrotic livers induced by carbon tetrachloride

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Circadian disruption accelerates liver carcinogenesis in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Identification of coding polymorphisms in human circadian rhythm genes PER1, PER2, PER3, CLOCK, ARNTL, CRY1, CRY2 and TIMELESS in a multi-ethnic screening panel.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

A functional polymorphism in PER3 gene is associated with prognosis in hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007

Common genetic variations in CLOCK transcription factor are associated with nonalcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.03.007